Editas MedicineEDIT

The company lost 15 cents per share last quarter, which was better than the 30 cent loss analysts expected. More importantly, recent financing has pushed its cash runway into the second half of 2028. This is a vital cushion for a biotech firm that is not yet making money, as it provides more time to reach clinical milestones without needing to immediately sell more stock.

The focus remains on EDIT-401, a treatment for heart disease that works inside the body. The company is on track to submit its clinical trial application this month and expects to share data from the study in early 2027. Early testing in animals showed a 90 percent reduction in bad cholesterol, but the real test will be whether those results translate to humans in the coming year.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Cash runway extended: The company now expects its $211.6 million in cash to fund operations into the second half of 2028, a major extension from the previous forecast of mid-2027. This provides a longer path to develop medicines without needing to immediately raise more money from investors.
• Revenue jump from partnerships: Revenue grew to $11.9 million from $3.6 million a year ago, primarily because certain partner rights expired and allowed the company to record previously delayed payments as current income. This accounting shift helped the company report a much smaller net loss of $18.2 million compared to $53.2 million in the same quarter last year.
• Research spending efficiency: Spending on research and development was $20.2 million this quarter, which is a significant drop from the $47.6 million pace seen in late 2024. While research costs rose by $4 million compared to last year to support new tests, the overall cost base is much lower after the company cut staff and stopped older programs.
• Key clinical milestone ahead: Management expects to submit a clinical trial notification this month and aims to provide a data update on its lead heart disease program, EDIT-401, in the first quarter of 2027. Meeting this timeline is critical because it represents the company's shift into testing its newest gene editing technology in humans.
• Capital position bolstered: A public stock offering in May brought in $125.0 million in gross proceeds, which is the main reason the cash balance rose from $146.6 million at the end of last year. If investors exercise all outstanding warrants, the company could receive another $194.4 million in the future.

Our take: A strong quarter that significantly derisks the business by pushing the cash runway into 2028. By cleaning up the balance sheet and narrowing the focus to EDIT-401, the company has bought itself the time needed to produce human data. This makes the long-term case much steadier.